bioMérieux, a world leader in the field of in vitro diagnostics, announces that VIDAS® 3, the new generation of VIDAS®, has been granted CE marking. This instrument, which further enriches the offering of the VIDAS immunoassay product range, VIDAS and mini VIDAS®, is now commercially available in Europe and the countries that recognize the CE marking.

bioMérieux, a world leader in the field of in vitro diagnostics, today announced that its novel molecular test THxIDTM-BRAF received PMA* approval from the FDA (Food and Drug Administration) for commercialization in the United States. This unique test is intended for the qualitative and simultaneous detection of both BRAF V600E and V600K mutations in late stage metastatic melanoma tumor samples.

bioMérieux, a world leader in the field of in vitro diagnostics, presented today VIDAS® 3, the new generation of its automated immunoassay system, during the Journées Internationales de Biologie (JIB) congress in Paris. This latest enhancement to the VIDAS® range offers major new features including, increased automation and greater traceability.